Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kent W Mouw

Showing results (61-70 of 121) with videos related to

Pageof 13
Sort By:
Brachytherapy|January 15, 2019
A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancerMartin T King, David D Yang, Vinayak Muralidhar, et al.
Urologic Oncology|December 26, 2017
Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancerMartin T King, Ming-Hui Chen, Brian J Moran, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2014
Proton radiation therapy for the treatment of retinoblastomaKent W Mouw, Roshan V Sethi, Beow Y Yeap, et al.
DNA Repair|September 10, 2019
Functional profiling of nucleotide Excision repair in breast cancerAnne S Rajkumar-Calkins, Raphael Szalat, Matija Dreze, et al.
European Urology|December 26, 2021
Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate RadiotherapyMatthew Mossanen, Filipe L F Carvalho, Vinayak Muralidhar, et al.
Clinical Genitourinary Cancer|December 3, 2017
Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active SurveillanceDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Cancer|August 24, 2017
Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Cancer Research|March 5, 2020
<i>ATM</i> Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate CancerShahrzad Rafiei, Kenyon Fitzpatrick, David Liu, et al.
Clinical Genitourinary Cancer|April 9, 2026
Radiation and Avelumab in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder CancerKent W Mouw, Kee-Young Shin, James Parisi, et al.
European Urology|December 18, 2018
Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate CancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Pageof 13

Showing results (61-70 of 121) with videos related to

Sort By:
Pageof 13
Brachytherapy|January 15, 2019
A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancerMartin T King, David D Yang, Vinayak Muralidhar, et al.
Urologic Oncology|December 26, 2017
Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancerMartin T King, Ming-Hui Chen, Brian J Moran, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2014
Proton radiation therapy for the treatment of retinoblastomaKent W Mouw, Roshan V Sethi, Beow Y Yeap, et al.
DNA Repair|September 10, 2019
Functional profiling of nucleotide Excision repair in breast cancerAnne S Rajkumar-Calkins, Raphael Szalat, Matija Dreze, et al.
European Urology|December 26, 2021
Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate RadiotherapyMatthew Mossanen, Filipe L F Carvalho, Vinayak Muralidhar, et al.
Clinical Genitourinary Cancer|December 3, 2017
Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active SurveillanceDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Cancer|August 24, 2017
Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Cancer Research|March 5, 2020
<i>ATM</i> Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate CancerShahrzad Rafiei, Kenyon Fitzpatrick, David Liu, et al.
Clinical Genitourinary Cancer|April 9, 2026
Radiation and Avelumab in Cisplatin-Ineligible Patients With Muscle-Invasive Bladder CancerKent W Mouw, Kee-Young Shin, James Parisi, et al.
European Urology|December 18, 2018
Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate CancerDavid D Yang, Brandon A Mahal, Vinayak Muralidhar, et al.
Pageof 13